Stock Analysis Report

Header cover image

Market Cap


Last Updated

2021/08/03 00:45 UTC

Data Sources

Company Financials +

Executive Summary

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. More Details

Snowflake Analysis

Fair value with mediocre balance sheet.

Similar Companies

Share Price & News

How has Chemours's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: CC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: CC's weekly volatility (6%) has been stable over the past year.

Market Performance

7 Day Return




US Chemicals


US Market

1 Year Return




US Chemicals


US Market

Return vs Industry: CC exceeded the US Chemicals industry which returned 35.3% over the past year.

Return vs Market: CC exceeded the US Market which returned 35.9% over the past year.

Shareholder returns

7 Day3.8%0.2%-0.4%
30 Day-5.7%-0.6%-0.4%
90 Day6.3%-3.0%4.0%
1 Year81.3%74.1%37.4%34.8%36.5%34.4%
3 Year-16.6%-27.7%41.3%20.3%62.0%51.9%
5 Year321.0%259.9%95.6%57.5%121.8%97.2%

Long-Term Price Volatility Vs. Market

How volatile is Chemours's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is Chemours undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: CC ($33.51) is trading below our estimate of fair value ($111.15)

Significantly Below Fair Value: CC is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: CC is good value based on its PE Ratio (21.7x) compared to the US Chemicals industry average (25x).

PE vs Market: CC is poor value based on its PE Ratio (21.7x) compared to the US market (18.2x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CC's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: CC is overvalued based on its PB Ratio (6.2x) compared to the US Chemicals industry average (3x).

Future Growth

How is Chemours forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?


Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CC's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if CC's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CC's revenue (5.3% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: CC's revenue (5.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CC's Return on Equity is forecast to be very high in 3 years time (47%).

Past Performance

How has Chemours performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CC has a large one-off loss of $92.0M impacting its June 30 2021 financial results.

Growing Profit Margin: CC became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: CC has become profitable over the past 5 years, growing earnings by -7.4% per year.

Accelerating Growth: CC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (25.6%).

Return on Equity

High ROE: Whilst CC's Return on Equity (28.44%) is high, this metric is skewed due to their high level of debt.

Financial Health

How is Chemours's financial position?

Financial Position Analysis

Short Term Liabilities: CC's short term assets ($3.0B) exceed its short term liabilities ($1.7B).

Long Term Liabilities: CC's short term assets ($3.0B) do not cover its long term liabilities ($4.9B).

Debt to Equity History and Analysis

Debt Level: CC's debt to equity ratio (433.8%) is considered high.

Reducing Debt: CC's debt to equity ratio has reduced from 2252% to 433.8% over the past 5 years.

Debt Coverage: CC's debt is well covered by operating cash flow (24.3%).

Interest Coverage: CC's interest payments on its debt are not well covered by EBIT (2.3x coverage).

Balance Sheet


What is Chemours's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Upcoming Dividend Payment

TodayAug 03 2021Ex Dividend DateAug 13 2021Dividend Pay DateSep 15 202133 days from Ex DividendBuy in the next 10 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: CC's dividend (2.98%) is higher than the bottom 25% of dividend payers in the US market (1.32%).

High Dividend: CC's dividend (2.98%) is low compared to the top 25% of dividend payers in the US market (3.55%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, CC has been paying a dividend for less than 10 years.

Growing Dividend: CC's dividend payments have increased, but the company has only paid a dividend for 6 years.

Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (64.6%), CC's dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: CC's dividends in 3 years are forecast to be well covered by earnings (24.7% payout ratio).

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Mark Newman (58 yo)





Mr. Mark E. Newman serves as Chief Executive Officer, President and Director at The Chemours Company since July 1, 2021. He joined Chemours in 2014. Mr. Newman served as the Chief Operating Officer of The ...

CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD3.00M) is below average for companies of similar size in the US market ($USD6.49M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: CC's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Board Members

Experienced Board: CC's board of directors are considered experienced (3.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

The Chemours Company's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: The Chemours Company
  • Ticker: CC
  • Exchange: NYSE
  • Founded: 2014
  • Industry: Diversified Chemicals
  • Sector: Materials
  • Market Cap: US$5.535b
  • Shares outstanding: 165.16m
  • Website: https://www.chemours.com

Number of Employees


  • The Chemours Company
  • 1007 Market Street
  • P.O. Box 2047
  • Wilmington
  • Delaware
  • 19899
  • United States



The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/03 00:45
End of Day Share Price2021/08/02 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.